NuCana (NASDAQ:NCNA) Announces Earnings Results

NuCana (NASDAQ:NCNA) issued its earnings results on Thursday. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($2.65) by $1.66, Zacks reports.

NuCana Stock Performance

NASDAQ NCNA traded up $0.05 during trading hours on Thursday, hitting $1.48. 15,645 shares of the company’s stock were exchanged, compared to its average volume of 35,395. The business’s 50 day moving average is $1.52 and its 200-day moving average is $1.87. NuCana has a 12-month low of $1.21 and a 12-month high of $7.22. The firm has a market capitalization of $6.16 million, a P/E ratio of -0.50 and a beta of 2.25.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, NuCana has a consensus rating of “Sell”.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.